CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Quick facts
Marketed products
- 200mg
- 400mg
- Sandostatin ® injection · Oncology; Endocrinology
Sandostatin (octreotide) is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells to inhibit the secretion of growth hormone, insulin, and other hormones.
Phase 3 pipeline
- Ammoxetine · Other
- Amphotericin B liposomes · Infectious Disease
Amphotericin B disrupts fungal cell membranes by binding to ergosterol, causing leakage of cellular contents and cell death. - DBPR108; Placebo matching sitagliptin · Diabetes
DBPR108 is a placebo matching formulation designed to match sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels to stimulate insulin secretion in response to glucose. - DP303c · Diabetes
DP303c is a small molecule that targets the SGLT2 receptor. - Hydroxocobalamin Chloride Injection · Hematology / Nutritional deficiency
Hydroxocobalamin chloride is a form of vitamin B12 that replaces deficient cobalamin and restores normal cellular metabolism and neurological function. - Meloxicam Nanocrystal Injection · Pain Management, Rheumatology, Inflammation
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation. - Placebo matching DBPR108; Sitagliptin; DBPR108 · Diabetes
Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and stimulate insulin secretion in response to glucose. - placepo · Other
- Salvage Chemotherapy · Oncology
Salvage chemotherapy refers to a combination chemotherapy regimen administered to patients who have failed or relapsed after initial cancer treatment. - semaglutide injection (HD1916) · Diabetes
Semaglutide injection works by mimicking the action of a natural hormone in the body called glucagon-like peptide-1 (GLP-1) to help lower blood sugar levels. - SKLB1028 · Oncology
SKLB1028 is a tyrosine kinase inhibitor that targets multiple kinases involved in cancer cell proliferation and survival. - SYH9056 · Oncology
SYH9056 is a small-molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival. - SYS6002
SYS6002 is a novel therapeutic agent in clinical development by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. - SYSA1901 · Oncology
SYSA1901 is a monoclonal antibody targeting PD-1.
Phase 2 pipeline
- Ammoxetine Hydrochloride Enteric-coated Tablets · Psychiatry
Ammoxetine hydrochloride is a norepinephrine reuptake inhibitor. - DP303c treatment
- Duloxetine hydrochloride enteric-coated capsules · Neurology
Selective serotonin and norepinephrine reuptake inhibitor - Glumetinib Tablets
- HA121-28 tablet
- rExenatide-4
- SYHA1402 tablets
Phase 1 pipeline
- [14C]DBPR108
- [14C] SKLB1028
- Albumin-bound docetaxel
- an antibody drug conjugate
- CSPCHA131
- DBPR108 tablets
- Drug: SYHA1801
- Drug: SYHA1805 tablets
- HA121-28 tablet A
- HA121-28 tablet B
- HA131
- Lenvatinib Mesilate Capsules
- Liposome-entrapped Mitoxantrone Hydrochloride Injection
- Octreotide Acetate Microspheres for Injection injection
- paclitaxel cationic liposomes
- Palbociclib tablet
- Probenecid tablets
- rE-4 Freeze-dried Powder
- SKLB1028 Dose Escalation
- SYH2085
- SYHA1805 tablets
- SYHA1807
- SYHX1903
- SYHX2001
- SYS6020
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: